BTIG Starts Agios Pharma (AGIO) at Neutral
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
BTIG initiated coverage on Agios Pharma (NASDAQ: AGIO) with a Neutral rating.
Analyst Ling Wang said, "We are initiating coverage of Agios Pharmaceutical (AGIO) with a Neutral rating. AGIO’s lead oncology assets, AG-221 and AG-120, have shown preliminary anti-tumor activities in AML. We view the market opportunity in AML as limited and the outcome of pivotal Phase III trials in R/R AML hard to handicap. The company’s rare genetic disease (RGD) program will probably become the key value driver, but we would await more definitive efficacy signals to become more bullish."
Shares of Agios Pharma closed at $40.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!